IXICO (LSE:IXI), the specialist provider of neuroimaging analysis for clinical trials, has been one of the more active small healthcare technology names on the FTSE AIM All Share index in 2026. The company launched a placing and subscription earlier in the year that targeted up to £10.5 million of new shares to scale its artificial intelligence-driven neurology platform, and its interim results for the six months to 31 March 2026 were headlined as showing continued solid Revenue and order book growth.

What the Company Does

IXICO analyses brain imaging data for pharmaceutical and biotechnology companies running Clinical Trials in neurological diseases. Its services help sponsors measure how experimental treatments affect the brain, using medical images such as MRI scans. The company's proprietary technology platform, known as IXI, applies automated and AI-driven analysis to these images, with the aim of producing consistent, high-quality data at scale across global studies.

Because its revenue comes from contracts linked to clinical trials, IXICO's performance depends on winning new studies, extending existing work and the progress of its customers' Drug Development programmes.

Latest Developments

The key corporate event of the year was the share fundraising. A placings and subscription announcement set out the company's plan to raise up to £10.5 million to accelerate the scaling of its platform, and a notice of meeting was published in 2026 in connection with Shareholder approvals. IXICO had previously completed a placing and subscription in October 2024.

On the operational side, the company has released the latest version of its AI-driven neuroimaging technology platform and has reported further validation of the automation capabilities of the IXI platform. It has also announced a contract extension worth around £1.5 million on a global phase 2 clinical trial. IXICO presented at the Mello 2026 investor event and took part in the BIO International Convention 2026, an important networking forum for the biotechnology industry.

Financial Picture

IXICO's financial year runs to 30 September. Its results for the year ended 30 September 2025 were published together with a notice of annual general meeting, and the interim results to 31 March 2026 pointed to growth in both revenue and the order book, which represents contracted work yet to be delivered. Exact revenue, loss and cash figures were not available at the time of writing and should be checked in the full announcements. The company does not pay a dividend, as it is focused on investing in growth.

Sector and Index Context

Neurology remains a major area of pharmaceutical research, including in Alzheimer's disease and other neurodegenerative conditions, and imaging biomarkers play an important role in many of these trials. Interest in applying AI to clinical research has grown firmly. Within the FTSE AIM All Share Index, IXICO is a small-cap company, and its shares can react sharply to contract news and funding announcements.

Key Risks

Risks include dependence on a limited number of large customers, the possibility of trials being delayed or cancelled for reasons outside the company's control, and competition from larger contract research organisations and imaging specialists. Share raises dilute existing shareholders, and delivering returns on the Investment in the platform is not guaranteed.

What to Watch Next

Investors will be watching for a trading update or full-year results covering the year to 30 September 2026, evidence that the new funding is translating into faster growth, further contract wins or extensions and any partnerships built around the IXI platform.